Merck & Co. Drops Kelun Claudin 18.2 ADC But Exercises Bispecific Option

 
• By Dexter Jie Yan
  
ADC
Merck brings onboard a bispecific antibody-drug conjugate while ditching a Claudin 18.2-targeting ADC from Kelun-Biotech. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

More from Scrip